Mesh slings for stress urinary incontinence: Informed decision-making only way out

Written By :  Medha Baranwal
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2023-11-24 21:00 GMT   |   Update On 2023-11-25 05:08 GMT

UK: A recent study published in European Urology Focus systematically reviewed the short- and long-term complications of mesh slings reported in observational data compared with clinical trial data. The study also determined whether the complication rates from clinical trials reflect "real-world" observational data.The researchers found that short- and long-term data on polypropylene mesh...

Login or Register to read the full article

UK: A recent study published in European Urology Focus systematically reviewed the short- and long-term complications of mesh slings reported in observational data compared with clinical trial data. The study also determined whether the complication rates from clinical trials reflect "real-world" observational data.

The researchers found that short- and long-term data on polypropylene mesh used for female stress urinary incontinence (SUI) are fairly comparable when using outcome data from well-designed clinical trials or less structured retrospective or prospective registries. However, the research team suggest making comparisons with caution since the two systems of data collection are inherently incomparable.

The complications of synthetic mid-urethral slings (MUSs) in women with SUI have become a globally debated issue. High-quality information is important to know whether mesh tapes used for stress incontinence treatment are safe and work well.

For the review, Fawzy Farag, Sohag University Hospital, Sohag, Egypt, and colleagues searched the online databases. They followed methods as detailed in Preferred Reporting Items for Systematic Reviews and Meta-analyses and Cochrane Handbook for Systematic Reviews of Interventions. Thirty registries/databases including 709 335 MUS procedures were identified.

Key findings were as follows:

  • MUS procedures were associated with intraoperative bladder perforation in 0.86-3.6%, urethral perforation in 0-0.1%, vascular injury in 0.04-0.1%, voiding lower urinary tract symptoms (LUTS) in 1.47-3.5%, vaginal exposure in 0.2-1.9%, and reoperation in up to 9% of cases.
  • Forty-three randomised clinical trials were identified, including 6284 women who underwent MUS procedures and 2177 women who underwent other interventions (1-10 years of follow-up).
  • MUS procedures were associated with urinary tract perforation in 2.58%, vaginal injury in 1.43%, de novo voiding LUTS in 4.37%, de novo storage LUTS in 5.41%, mesh extrusion/exposure (vaginal/urinary tract) in 2.54%, dyspareunia in 2.26%, pain (pelvic/suprapubic/perineal) in 2.83%, and reoperation for complications required in 1.82% of cases.
  • Meta-analyses of the randomised controlled trials revealed that retropubic MUSs were associated with more events of urinary tract perforation (risk ratio [RR] 9.81, high certainty of evidence [COE]) and voiding LUTS (RR 1.57, high COE) than transobturator MUSs.
  • MUSs were associated with more events of pain than mini-slings (RR 1.72, moderate COE).

"Well-designed clinical studies give similar results to large registration databases," the researchers wrote. "These data should be interpreted with caution given the different ways of the information collection."

"These results will help physicians and patients understand the risks of mesh tapes," they concluded.

Reference:

Farag F, Osman NI, Pang KH, Castro-Diaz D, Chapple CR, Cruz F, Gamé X, Goldman H, Greenwell T, Hampel C, Scailteux LM, Roovers JP, Welk B, Heesakkers J. Complications of Synthetic Midurethral Slings: Is There a Relevant Discrepancy Between Observational Data and Clinical Trials? Eur Urol Focus. 2023 Nov 14:S2405-4569(23)00244-4. doi: 10.1016/j.euf.2023.11.002. Epub ahead of print. PMID: 37973453.


Tags:    
Article Source : European Urology Focus

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News